Enrollment in the ongoing phase II study CARRIE is finally over and Merrimack Pharmaceuticals Inc (NASDAQ:MACK) is excited that everything played out as expected. The study was organized to help evaluate the provider’s pipeline candidate MM-141 (istiratumab) in combination with standard of Care.This Company hopes that it will soon be able to assist all patients that have been struggling with previously untreated metastatic pancreatic cancer.
FDA had in Nov 2014 granted an orphan drug designation to MM-141 and one of the top officials working with Merrimack Pharmaceuticals Inc outlined that they were optimistic they were the ones that would introduce the best solution to help handle pancreatic cancer treatment.
The President and Chief Executive Officer of Merrimack, Richard Peters when recently addressing a press conference said, “Today, as we recognize the 10th anniversary of the National Pancreatic Cancer Advocacy Day, we are marking a significant milestone with the CARRIE study, which reflects both the significant need for new therapies in metastatic pancreatic cancer and the potential of MM-141 to play a critical role in addressing that need.”
According to Yahoo.com, Richard Peters also added to say that they were mobilizing resources to see to it that the study turned out to be a great success. He added that they hoped each of their clinical -stage development programs would run as planned to help them make important discoveries in the medical field.
The investigation of a biomarker-driven treatment strategy is crucial to the provider and it seeks to efficiently establish the role of its therapies for the well-defined patient groups. It is a transformative moment for the company considering that the enrollment is already complete. Most probably, by the first half of 2018 the company will be ready to report results from the trial.
Medical Director and Project Leader for MM-141, Vasileios Askoxylakis, recently addressed some top journalists where he spoke on behalf of the company’s entire team. He said that they greatly appreciated the great job done by investigators and their staff for their dedication in ensuring the rapid execution of this study.